2021
DOI: 10.1016/j.waojou.2021.100547
|View full text |Cite
|
Sign up to set email alerts
|

Variability of Type 2 inflammatory markers guiding biologic therapy of severe asthma: A 5-year retrospective study from a single tertiary hospital

Abstract: Background Currently, biotherapy is mainly administered to treat patients with severe asthma with the Type 2 (T2) inflammation phenotype. The variability of T2 inflammatory markers remains poorly understood. Objective We aimed to describe the individual distributions of different biomarkers at varying thresholds and their variation patterns in participants with severe asthma. Methods We retrospectively reviewed the … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
10
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 10 publications
(10 citation statements)
references
References 47 publications
0
10
0
Order By: Relevance
“…This suggests that the increase in percentage of sputum eosinophils is more likely from natural variations in sputum eosinophil count over time. 49 Lastly, a major limitation is that prednisolone was given during stable rather than exacerbation state. As such, patients had wellcontrolled asthma symptoms, which may not be amenable to further improvements.…”
Section: Discussionmentioning
confidence: 99%
“…This suggests that the increase in percentage of sputum eosinophils is more likely from natural variations in sputum eosinophil count over time. 49 Lastly, a major limitation is that prednisolone was given during stable rather than exacerbation state. As such, patients had wellcontrolled asthma symptoms, which may not be amenable to further improvements.…”
Section: Discussionmentioning
confidence: 99%
“…. 300 cells/mL threshold was chosen only 22% of the participants continued to exceed the cut-off value over time (34).…”
Section: Variability Of Blood Eosinophiliamentioning
confidence: 99%
“…Moderately better results were demonstrated in a more restricted population of 75 uncontrolled asthmatic patients, yielding a significant positive relationship between the percentage of S-EOS and B-EOS ( r = 0.3647), yet limited by the use of the cut-off point of B-EOS of 1.5% of WBC ( 33 ). Higher sensitivity and specificity and AUC as a biomarker of S-EOS (≥3%) in a population of uncontrolled asthmatics were reported to increase the peripheral B-EOS cut-off percentage to 2.7% ( 34 ). A systematic review and meta-analysis including 14 studies investigating B-EOS as a predictor marker for airway eosinophilia in patients with asthma yielded overall a modest capacity to distinguish between patients with or without airway eosinophilia (AUC of 0.78) and either eosinophil ≥2 or >3% did not affect the accuracy of the test ( 35 ).…”
Section: Systemic Biomarkersmentioning
confidence: 99%
See 2 more Smart Citations